The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, describes the process and outcomes of the Phase 1b trial (NCT02715531) investigating the combination of bevacizumab and atezolizumab for advanced hepatocellular carcinoma (HCC) patients, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. With a tolerable safety profile, encouraging response rates and durable responses, this may be a promising first-line treatment option for patientss with advanced HCC. The Phase III IMbrave150 trial (NCT03434379) is currently recruiting.
